TrialSignal transduction and targeted therapy2026

Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.

Yi Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.